(NP (NP (NP (NN Signaling)) (PP (IN via) (NP-COOD (NP (NN IL-2)) (CC and) (NP (NN IL-4)))) (PP (IN in) (NP (JJ JAK3-deficient) (JJ severe) (JJ combined) (NN immunodeficiency) (NNS lymphocytes))) (: :)) (NP (ADJP-COOD (ADJP (JJ JAK3-dependent)) (CC and) (ADJP (NP (-NONE- *?*)) (JJ independent))) (NNS pathways)) (. .))
(S (NP-SBJ-COOD (CC Both) (NP (NN IL-2)) (CC and) (NP (NN IL-4))) (VP (VBP bind) (PP (TO to) (NP (NP (NNS receptors)) (VP (VBG containing) (NP-COOD (NP (DT the) (JJ common) (NN gamma) (NN chain)) (CC and) (NP (NN JAK3))))))) (. .))
(S (SBAR (IN Although) (S (NP-SBJ-100 (NN JAK3)) (VP (VBZ is) (VP (VBN required) (NP (-NONE- *-100)) (PP (IN for) (NP (JJ proper) (JJ lymphoid) (NN development))))))) (, ,) (NP-SBJ-39 (NP (DT the) (JJ precise) (NNS roles)) (PP (IN of) (NP (DT this) (NN kinase))) (PP (IN in) (NP (NP (NP-COOD (NP (NN IL-2)) (CC and) (NP (NN IL-4))) (NN signaling)) (PP (IN in) (NP (NNS lymphocytes)))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN defined) (NP (-NONE- *-39))))) (. .))
(S (ADVP (RB Here)) (, ,) (NP-SBJ (PRP we)) (VP (VBP have) (VP (VBN studied) (NP (NP (NP-COOD (NP (NN IL-2)) (CC and) (NP (NN IL-4))) (NN signaling)) (PP (IN in) (NP (NP (NN B) (NN cell) (NNS lines)) (VP (VBG lacking) (NP (NN JAK3)))))))) (. .))
(S (SBAR (IN Although) (S (NP-SBJ (NP (JJ IL-2-induced) (NN phosphorylation)) (PP (IN of) (NP-COOD (NP (NN IL-2R) (NN beta)) (, ,) (NP (NN JAK1)) (, ,) (CC and) (NP (NN STAT5)))) (ADVP (DT all))) (VP (VBN required) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN JAK3))))))) (, ,) (NP-SBJ (NP (JJ IL-4-mediated) (NN phosphorylation)) (PP (IN of) (NP-COOD (NP (NN JAK1)) (, ,) (NP (NN STAT6)) (, ,) (CC and) (NP (NN insulin) (NN receptor) (NNS substrates) (NP-COOD (NP (CD 1)) (CC and) (NP (CD 2))))))) (VP (VBD did) (RB not) (VP (-NONE- *?*))) (. .))
(S (ADVP (RB However)) (, ,) (NP-SBJ-40 (JJ IL-4-induced) (NNS effects)) (VP (VBD were) (VP (ADVP (RB clearly)) (VBN improved) (NP (-NONE- *-40)) (PP-TMP (VBG following) (NP (NN JAK3) (NN expression))))) (. .))
(S (NP-SBJ (DT These) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ (NN IL-4) (NN signaling)) (VP-COOD (VP (VBZ occurs) (PP (IN in) (DT the) (NN absence) (IN of) (IN of) (NP (NN JAK3)))) (, ,) (CC but) (VP (VBZ is) (ADJP-PRD (RB comparatively) (JJ inefficient))))))) (. .))
(S (NP-SBJ (DT These) (NNS findings)) (VP-COOD (VP (MD may) (VP (VB help) (PP (RP in) (S (NP-SBJ (-NONE- *)) (VP (VBG understanding) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (NP (DT the) (NN immunodeficiency)) (SBAR (WHNP-41 (WDT that)) (S (NP-SBJ (-NONE- *T*-41)) (VP (VBZ occurs) (PP (IN with) (NP (NP (NNS mutations)) (PP (IN of) (NP (NN JAK3)))))))))))))))) (CC and) (VP (MD may) (VP (VB suggest) (NP (NP (DT a) (NN mechanism)) (PP (IN for) (NP (NP (DT the) (JJ pleiotropic) (NNS effects)) (PP (IN of) (NP (NN IL-4))))))))) (. .))
